AzTrials
AzTrials

Parent-Child RelationsNCT04818112

A Randomized Controlled Trial to Improve Mother-Infant Synchrony Among Women With Childhood Adversity

A study testing ATVV in people with Parent-Child Relations and Maternal Behavior, run by University of Arizona at 2 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Childhood adversity affects almost two-thirds of the US population, is a major risk factor for the leading causes of disease and increases US economic health burdens. Childhood adversity also alters biologic systems, such as the oxytocin hormone, that can affect attachment behavior. Read more about this study

Who is it for?
Ages 18 years and older, women onlyHealthy volunteers can take part
What is being tested?
ATVV
Could I receive a placebo?
No, everyone receives an active treatment
How many people
262 participants
Where
2 sitesUnited States
Study dates
12 Jul 2021to 17 Jun 2024
Phase
Interventional
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Pregnant
  • Healthy (gestational diabetes is acceptable)
  • Greater than or equal to 18 years old
  • Nulliparous (previous miscarriage(s) and/or abortion(s) acceptable)
  • Speak and read English or Spanish
  • Score greater than or equal to 2 on the Adverse Childhood Experience (ACE) survey
Show all 9Show fewer
  • Expect to deliver a healthy infant
  • Expect to deliver a full-term infant (greater than or equal to 37 weeks and 0/7 days)
  • Expect to deliver a singleton infant

Who cannot join

  • Multiparous
  • Have no access to a cell phone during the first 3 postnatal months
  • Carrying multiple fetuses
  • Taking anti-depressant(s) during pregnancy
  • Taking illicit drugs
  • Do not speak and read English or Spanish;
Show all 26Show fewer
  • Under 18 years of age
  • Score less than 2 on the Adverse Childhood Experience (ACE) survey
  • Deliver an infant diagnosed with conditions that could affect normal development or the oxytocin system
  • Pre-term gestation (less than 37 weeks and 0/7 days)
  • Intrauterine growth retardation (IGR)
  • Small for gestational age (SGA)
  • Chromosomal anomaly including
  • Down syndrome (trisomy 21)
  • Trisomy 13
  • trisomy 18
  • Klinefelter syndrome
  • Turner syndrome
  • Triple X syndrome
  • Congenital anomaly including
  • Heart defect
  • Musculoskeletal defect
  • Neural tube defect
  • Cystic Fibrosis
  • Haemophilia
  • Microcephaly

Trial locations and contacts

2 sites in 1 country.

United States2 sites
  • Tucson Medical Center

    Tucson, Arizona, 85712

  • Banner University Medical Center - Tucson

    Tucson, Arizona, 85719

Other trials in United States

About this study

Childhood adversity affects almost two-thirds of the US population, is a major risk factor for the leading causes of disease and increases US economic health burdens. Childhood adversity also alters biologic systems, such as the oxytocin hormone, that can affect attachment behavior. This innovative study has the potential to advance science and improve mother-infant interaction by testing an early life, home-based, multisensory behavioral intervention (called ATVV), targeting the oxytocin system, to promote synchronous early mother-infant interaction, especially critical for mothers who have experienced childhood adversity.

This two-group randomized clinical trial will test the ATVV's effect on oxytocin system function and quality of mother-infant interaction. The investigators will enroll 250 first-time healthy mothers carrying a single baby who have a history of childhood adversity, and obtain baseline data in their third trimester of pregnancy. Soon after birth (before hospital discharge), mothers (and babies) who continue to be eligible are randomized into the intervention group and taught to give ATVV daily for 3 months, or randomized into the Attention Control education group and taught safe infant care. After birth, the investigators check-in frequently with mothers through weekly phone calls. There are 3 study visits at 1, 2 and 3 months after birth that include survey questions and collection of maternal blood and infant saliva. Mothers and babies are also video-recorded at 3 months after birth for 4 minutes to assess mother-infant interaction. The investigators follow-up with a phone call at 6 months after birth.

While both groups will benefit from the content and attention the investigators give mothers, the investigators hypothesize that, compared to the education group, mothers and infants in the intervention group will have improved oxytocin system function and more synchronous mother-infant interaction.

Read the detailed description

Childhood adversity (e.g., abuse, neglect, or household dysfunction), is a common experience significantly contributing to the leading causes of death and increased US economic health burdens. Childhood adversity causes long-term alterations on the nervous, endocrine, and immune systems well into adulthood, including dampening of the neuropeptide oxytocin (OXT). A healthy OXT system facilitates responsive social engagement and promotes maternal-infant (M-I) synchrony (reciprocal gaze, affect speech, and touch). Optimal M-I synchrony fuels early brain development and prevents low empathy, disruptive behavior, poor social adaptation, cognitive deficits, and psychopathology in children. The investigators posit that mothers with childhood adversity will have more difficulty with M-I synchrony, due in part to a dampened OXT system, and will benefit from interventions that improve responsive, nurturing, engagement by epigenetic regulation of the OXT system. Most interventions are costly, complex, and time-consuming. The investigators aim to fill this gap by testing whether a simple early behavioral intervention (ATVV) will improve OXT system function and M-I synchrony in mothers with childhood adversity.

The ATVV (Auditory, Tactile, Visual, Vestibular) is a 15-minute behavioral intervention that is a multisensory infant massage contingent on infant cues. The investigators extend the known success of ATVV with preterm infants to full-term infants. The investigators will compare M-I synchrony at 3 postnatal months in 250 first-time mothers (and their full-term infants) randomized to apply ATVV daily from birth to 3 months (n =125) or receive infant care education in an attention control group (n = 125). The investigators apply a rigorous measure of M-I synchrony that micro-codes video-recorded M-I behavior quantifying shared gaze, affect, speech, and touch. Coding requires only 3-minutes of interaction and is valid when infants can reliably interact starting by 3 months of age. The investigators will also assess ATVV's effect on maternal and infant peripheral OXT level, a known biomarker of M-I synchrony. OXT levels relate to quality of M-I synchrony, yet the investigators extend this knowledge to identify an epigenetic role of the oxytocin receptor gene (OXTR). The investigators will analyze maternal plasma for OXTR methylation, OXTR gene expression, OXTR protein, and oxytocin peptide in pregnancy, and at 1, 2, and 3 postnatal months (along with infant saliva OXT).

The investigators propose a single-site, randomized, two-group, attention-controlled clinical trial (N=250 M-I dyads) to test the efficacy of the ATVV multisensory behavioral intervention to improve OXT system function and M-I synchrony. Adult, nulliparous, English or Spanish speaking women carrying a single fetus, and scoring 2 or higher on the Adverse Childhood Experiences scale will be enrolled. The investigators will obtain baseline OXT, demographics and survey data in the third trimester. Soon after birth (pre-hospital discharge), M-I dyads who continue to be eligible (e.g., full-term gestation) are randomized into the intervention group (n = 125) and taught to administer ATVV daily for 3 months or randomized into the Attention Control group (n = 125) and taught normal safe infant care. There are postnatal study visits at 1, 2 and 3 months. The investigators follow-up with a phone call at 6 postnatal months (3-months after the intervention period ends) to assess self-report parenting behavior (a proxy for quality of M-I interaction) that the investigators also measure at postnatal months 1, 2, and 3.

Aim 1: Evaluate the efficacy of daily ATVV over 3 postnatal months among mothers with childhood adversity. The investigators hypothesize that compared to the Attention Control group (n=125), M-I dyads in the ATVV group (n=125) will exhibit:

H1: Higher oxytocin function (i.e., decreased OXTR methylation at candidate sites, and increased OXTR messenger ribonucleic acid (mRNA), OXTR protein, and OXT in maternal plasma, and increased OXT in infant saliva) at 1, 2, and 3 postnatal months.

H2: More synchronous eye-to-eye gaze [primary], positive affect [primary], speech, and touch at 3 postnatal months.

Aim 2: Identify molecular mechanisms in the OXT system underlying M-I synchrony (N=250).

H1: Lower M-I synchrony will be associated with dampening of the OXT system, evidenced by increased OXTR methylation at candidate sites, and decreased OXTR mRNA, OXTR protein, and OXT in maternal plasma, and decreased OXT in infant saliva at 3-postnatal months.

Regression based methods (including covariates) will assess ATVV effects on M-I synchrony and OXT measures, and identify relations among M-I synchrony and oxytocin measures. Clustering methods will be used to discover molecular profiles. An early behavioral intervention that successfully promotes M-I synchrony in vulnerable women through epigenetic regulation of the OXT system can then be tested in a multi-site clinical implementation trial with other high-risk groups.

Protocol: The Recruiter will introduce the study to potentially eligible pregnant women. Eligible women who are interested in joining will be consented and scheduled for a 3rd trimester baseline study visit at the university. The investigators will draw blood for OXT measures, and collect data in REDCap on demographics, maternal characteristics, and self-report surveys. Research team members will keep track of when participants have given birth and meet them in a study site hospital before discharged. The investigators will collect data on mother and infant health, birth events, and other covariates. At the hospital visit, women are randomly assigned to either the ATVV group and taught how to administer the intervention on a daily basis, or are randomly assigned to the Attention Control group and taught safe infant newborn care.

All participants will receive daily texts to measure daily stress, and intervention participants also document frequency of the intervention. Using Participatory Guidance to address women's needs, the investigators will call women each week after birth for a check-in. In the intervention group, any challenges with the intervention will be discussed and problem-solved. In the Attention Control group, age-appropriate safe infant care will be discussed.

After the hospital visit, monthly study visits at 1, 2, and 3 months include collecting maternal blood and infant saliva, and self-report surveys in REDCap. Women will either complete REDCap surveys online before each visit, or complete them at the study visit. To check intervention fidelity, mothers in the ATVV group demonstrate how they perform the intervention with their infant. The team member instructs mothers how to adapt the ATVV to their maturing infant and discuss any challenges with the intervention. Mothers in the Attention Control group are taught age-appropriate safe infant care.

At the 3rd month study visit, the investigators collect behavioral outcome data on M-I synchrony. All M-I dyads will be video recorded freely interacting with each other for 4 minutes (coding occurs on the last 3 minutes). Video recording occurs when the infant is alert and ready to interact, > 30 minutes after the end of a breastfeeding or formula feeding, and data collection order may be adjusted if the baby is sleepy or fussy. Interactions are micro-coded frame by frame on a computerized system (Noldus, Wageningen, The Netherlands), consistent with previous research on parent-infant synchrony. Coders, blinded to group assignment, are trained to 90% inter-rater reliability. Our last interaction with participants is a phone call at 6-postnatal months to explore duration of the intervention's effect using the Parenting Stress Index.

Being tested
ATVV, Attention control
Keywords
Oxytocin, DNA methylation, Massage, Mothers, Infant, Adverse childhood experiences, Mother-infant interaction, Maternal behavior, Infant behavior, Receptor, oxytocin, Randomized controlled trial
Medical subject headings
Infant Behavior

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ATVVBehavioural

    Also called multisensory infant massage plus

    A 15-minute behavioral intervention that mothers administer once daily to their infant for 3 months providing Auditory, Tactile, Visual, and Vestibular (ATVV) stimulation. Multisensory stimuli are presented in gradual progression. Mother-infant engagement is attempted throughout ATVV so that mothers learn to identify, interpret and adapt to their infants cues. ATVV can be given without eye to eye gaze making it appropriate for newborns. ATVV is offered contingent on infant cues to promote self-regulation and withdrawn if any persistent disengagement cues. Mothers are taught how to adapt ATVV as their infant grows. Fidelity to the intervention is checked with weekly phone calls and monthly study visits. Mothers also receive a daily text from REDCap to document an intervention frequency log.

  • Attention controlBehavioural

    Mothers in the Attention Control group receive a similar amount of daily texts, weekly phone call and in-person study visit attention as mothers in the ATVV group, but with distinctly different content. Over the first 3 postnatal months, mothers learn safe infant-care that includes content on diapers, infant clothing, blankets, infant care including bathing, sleep positions, sleep habits, holding the baby, safety of infant equipment, breastfeeding, formula, and age appropriate toys.

Study groups in NCT04818112
Study groupRoleWhat they receive
Behavioral ATVV interventionExperimentalA multi-sensory behavioral intervention that includes auditory, tactile, visual and vestibular (ATVV) stimulation contingent upon infant cues.
Receives: Behavioral: ATVV
Attention controlActive comparatorAn attention control group that receives education on safe infant care and the same amount of attention as the intervention group.
Receives: Behavioral: Attention control

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mother-Infant Synchrony, Gaze and Affect

    Video-recordings of mothers freely interacting with their infant were micro-coded second by second for the number of seconds of mother-infant synchrony over 180 seconds. Behaviors are categorized into mutually exclusive codes. The most robust behavior categories for mothers and infants (individually and in synchrony) are gaze and affect. Maternal gaze consisted of mother's gaze to infant's face, to infant's body, to object or environment, and gaze aversion. Infant gaze consisted of gaze to mother, gaze to object or environment, and gaze aversion. Maternal affect consisted of positive, neutral, and negative affective expression. Infant affect consisted of high positive (laugh, giggle, smile), positive (smile, bright face), negative (sad face, occasional whimper), high negative (cry, strong whining), or neutral.

    Measured: 84 +/- 7days from birth (approximately 3 months after birth)

Secondary outcomes (6)
  1. Mother-Infant Synchrony, Vocalization and Touch

    Video-recordings of mothers freely interacting with their infant were micro-coded second by second for the number of seconds of mother-infant synchrony over 180 seconds. Behaviors are categorized into mutually exclusive codes. The second most robust behavior categories for mothers and infants (individually and in synchrony) are vocalization and touch. Maternal vocalization consisted of motherese positive speech (infant-directed speech typically high-pitched with a sing-song rhythm), adult speech to the infant in a normal range and regular rhythm, adult speech to other adult, and no speech. Infant vocalization consisted of positive (babbling, cooing, or giggles) and negative (fussing or crying).

    Measured: 84 +/- 7days from birth (approximately 3 months after birth)

  2. Oxytocin Receptor Gene DNA Methylation Reflecting Epigenetic Marks

    Using maternal plasma, % OXTR DNA methylation will be measured at candidate cytosine-phosphate-guanosine (CpG) sites -1001, -959, -934, -924, -901, and -860 that were selected based on their implication in previous studies relating to psychosocial behaviors. There is also cost-effectiveness in using the selected assay to co-target additional CpG regions implicated in the literature relating to psychosocial behaviors. Methylation is measured using bisulfite conversion (EZ DNA Lightning Kit), followed by high-throughput next-generation sequencing of polymerase chain reaction (PCR) amplicons (Illumina MiSeq) at the University of Arizona Genetics Core.

    Measured: Baseline at 31weeks +/- 2 weeks gestation and every 28 days +/- 7 days from birth to 3 months

  3. Oxytocin Receptor Gene Expression

    Using maternal plasma, OXTR mRNA level will be measured using quantitative Real-Time PCR (qRT-PCR) that demonstrates total OXTR gene expression. This reflects the DNA transcribed (copied) into RNA before translation produces protein. Analysis is performed by the College of Nursing Biological Core Laboratory.

    Measured: Baseline at 31weeks +/- 2 weeks gestation and every 28 days +/- 7 days from birth to 3 months

  4. Oxytocin Receptor Protein

    Using maternal plasma, total protein expression of OXTR will be measured to reflect the amount of OXT receptors available to bind with OXT peptides. Analysis is performed by the College of Nursing Biological Core Laboratory using Anti-OXTR antibody and Western Blot (considered to be the gold standard).

    Measured: Baseline at 31weeks +/- 2 weeks gestation and every 28 days +/- 7 days from birth to 3 months

  5. Oxytocin Peptide, Maternal Plasma

    Using maternal plasma, the ELISA assay will be used to report OXT peptide level. Samples are analyzed at the University of Arizona Laboratory for the Evolutionary Endocrinology of Primates (LEEP) in duplicate by enzyme immunoassay (EIA) using the Oxytocin ELISA kit (Enzo; ADI-901-153A-0001).

    Measured: Baseline at 31weeks +/- 2 weeks gestation and every 28 days +/- 7 days from birth to 3 months

  6. Oxytocin Peptide, Infant Saliva

    Using infant saliva, the ELISA assay will be used to report OXT peptide level. Samples are analyzed at the University of Arizona Laboratory for the Evolutionary Endocrinology of Primates (LEEP) in duplicate by enzyme immunoassay (EIA) using the Oxytocin ELISA kit (Enzo; ADI-901-153A-0001).

    Measured: Every 28 days +/- 7 days from birth to 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Mar 2021
  2. Study start12 Jul 2021
  3. Primary completion8 Mar 2024
  4. Study completion17 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
This randomized clinical trial uses group comparison of an intervention group and an education control group.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
262 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04818112
Sponsor's protocol ID
2009050756
Status last verified
Jul 2025
First submitted
23 Mar 2021
Last updated
13 Aug 2025
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Bell AF, Feldman R, Bedrick EJ, Fisher JM, Carter CS, MacLean EL, Tecot SR, White-Traut R. The efficacy of Massage+ on mother-infant synchrony in mothers with childhood adversity: A randomized controlled trial. Dev Psychol. 2026 Aug 31. doi: 10.1037/dev0002255. Online ahead of print.

    PubMed 42671818
  • Jones KA, Freijah I, Brennan SE, McKenzie JE, Bright TM, Fiolet R, Kamitsis I, Reid C, Davis E, Andrews S, Muzik M, Segal L, Herrman H, Chamberlain C. Interventions from pregnancy to two years after birth for parents experiencing complex post-traumatic stress disorder and/or with childhood experience of maltreatment. Cochrane Database Syst Rev. 2023 May 4;5(5):CD014874. doi: 10.1002/14651858.CD014874.pub2.

    PubMed 37146219

Questions about this trial

What is this clinical trial studying?

A study testing ATVV in people with Parent-Child Relations and Maternal Behavior, run by University of Arizona at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Aug 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mother-Infant Synchrony, Gaze and Affect (time frame: 84 +/- 7days from birth (approximately 3 months after birth)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04818112, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in